← ANALYST RATINGS · TIPRANKS

Abbott Laboratories (ABT): analyst forecast and price target

$105 +0.20% close 16.10.26 · market cap $178B · Healthcare · Medical - Devices SPY 0.27%
Price targets and ratings of

Analyst consensus

Strong Buy

7 Buy0 Hold0 Sell

Ratings of 7 analysts in the last 3 months · top analysts only

12-month forecast

$124+17.8% upside

Based on 7 price targets given in the last 3 months, the average target is $124, the highest $135, the lowest $112. The average is +17.8% from the last price of $105.

$80.00$100$120Jan 26AprJulOctJan 27AprJulOctHigh$135Average$124Low$112
Highest target $135 Average target $124 Lowest target $112
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% TD Cowen $135 Buy +28.7% Reiterated 16.10.26on TipRanks 08:30 +1.3%
Unknown Analyst Leerink Partners — Hold — Reiterated 12.10.26on TipRanks Oct 13 11:05 +2.3%next day +0.8%
Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% Barclays $120 Buy +14.4% Initiated 07.10.26on TipRanks 03:55 +0.8%next day +0.2% · 5 days +5.3%
Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% Citi $125 Buy +19.2% Reiterated 05.10.26on TipRanks 07:21 +2.0%next day −2.5% · 5 days +1.3%
Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% Wells Fargo $112 Buy +6.8% Reiterated 05.10.26on TipRanks 07:16 +2.0%next day −2.5% · 5 days +1.3%
Ed Ridley-Day★★★★★★★★★★#5780 · hits 54% · avg +8.0% Rothschild & Co Redburn $119 → $127+6.7% Buy +21.1% Upgrade 02.10.26on TipRanks 05:07 +0.1%next day +2.0% · 5 days +1.0%
Name not given — $130 Buy +23.9% Reiterated 01.10.26on TipRanks Oct 2 21:45 −2.3%next day +0.1% · 5 days +0.6%
Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% Bank of America Securities $115 Buy +9.6% Reiterated 01.10.26on TipRanks Oct 2 05:07 −2.3%next day +0.1% · 5 days +0.6%
Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% Wells Fargo $112 Buy +6.8% Reiterated 29.09.26on TipRanks Sep 30 04:50 +0.2%next day −1.9% · 5 days −4.7%
Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% TD Cowen $135 Buy +28.7% Reiterated 14.09.26on TipRanks 06:30 +1.6%next day −0.6% · 5 days −2.0%
Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% Citi $125 Buy +19.2% Reiterated 10.09.26on TipRanks 06:10 −1.2%next day −2.2% · 5 days −1.7%
Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% J.P. Morgan — Buy — Reiterated 01.09.26on TipRanks 09:15 −0.6%next day +1.0% · 5 days −3.5%
Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% Piper Sandler $118 Buy +12.5% Reiterated 26.08.26on TipRanks 07:35 −1.8%next day −2.9% · 5 days −3.1%
Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% Jefferies $135 Buy +28.7% Reiterated 21.08.26on TipRanks 12:16 +1.8%next day +0.3% · 5 days −4.0%
Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% William Blair — Buy — Reiterated 21.08.26on TipRanks 04:55 +1.8%next day +0.3% · 5 days −4.0%
Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% Bank of America Securities $115 Buy +9.6% Reiterated 20.08.26on TipRanks Aug 21 06:50 +0.6%next day +1.8% · 5 days −3.3%
Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% BTIG $134 Buy +27.8% Reiterated 20.08.26on TipRanks Aug 21 06:27 +0.6%next day +1.8% · 5 days −3.3%
Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% Wolfe Research $130 Buy +23.9% Upgrade 13.08.26on TipRanks 06:10 −0.4%next day +0.2% · 5 days +4.5%
Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% UBS $135 → $125−7.4% Buy +19.2% Assigned 28.07.26on TipRanks 08:22 +2.4%next day +2.2% · 5 days −5.8%
Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% Raymond James — Buy — Reiterated 17.07.26on TipRanks Jul 19 10:35 +2.9%next day +1.1% · 5 days +3.0%
Shagun Singh Chadha★★★★★★★★★★#9557 · hits 48% · avg −0.4% RBC Capital $130 Buy +23.9% Reiterated 16.07.26on TipRanks Jul 17 07:06 +11.3%next day +2.9% · 5 days +3.6%
Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% Evercore ISI $120 → $112−6.7% Buy +6.8% Reiterated 06.07.26on TipRanks 08:45 −0.6%next day +0.7% · 5 days −3.4%
David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% Robert W. Baird $121 Buy +15.4% Initiated 30.06.26on TipRanks 16:25 +1.7%next day +3.6% · 5 days +1.6%
David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% Goldman Sachs $121 → $113−6.6% Buy +7.7% Reiterated 31.05.26on TipRanks Jun 1 08:35 +2.3%next day −1.1% · 5 days +5.6%
Narumi Nakagiri★★★★★★★★★★#5254 · hits 64% · avg +9.1% Daiwa $113 → $92.00−18.6% Hold −12.3% Downgrade 21.04.26on TipRanks 20:30 −2.1%next day +1.2% · 5 days −0.5%
Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% Mizuho Securities $125 → $115−8.0% Hold +9.6% Reiterated 20.04.26on TipRanks 08:15 −0.6%next day −2.8% · 5 days −4.2%
Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% Barclays $144 → $143−0.7% Buy +36.3% Assigned 20.04.26on TipRanks Apr 17 04:10 +0.2%next day −0.6% · 5 days −6.4%
Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% Oppenheimer $132 → $115−12.9% Buy +9.6% Reiterated 17.04.26on TipRanks 21:15 −0.6%next day −2.8% · 5 days −4.2%
Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% Benchmark Co. $145 → $120−17.2% Buy +14.4% Reiterated 17.04.26on TipRanks 07:10 +0.2%next day −0.6% · 5 days −6.4%
Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% Stifel Nicolaus $145 → $120−17.2% Buy +14.4% Assigned 17.04.26on TipRanks 06:55 +0.2%next day −0.6% · 5 days −6.4%
Unknown Analyst Erste Group — Hold — Reiterated 01.04.26on TipRanks Apr 2 23:30 −1.0%next day +0.4% · 5 days −3.4%
Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% Bernstein $154 → $125−18.8% Buy +19.2% Reiterated 23.01.26on TipRanks 07:25 −1.1%next day +0.7% · 5 days +1.4%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Abbott Laboratories

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Matthew Taylor★★★★★★★★★★Jefferies · #1367
Hits 55%250 of 455 Average return +7.2%
1 year Jayson Bedford★★★★★★★★★★Raymond James · #819
Hits 60%299 of 498 Average return +8.6%
2 years Matthew Taylor★★★★★★★★★★Jefferies · #1367
Hits 55%250 of 455 Average return +7.2%

Most profitable

3 months Jayson Bedford★★★★★★★★★★Raymond James · #819
Hits 60%299 of 498 Average return +8.6%
1 year Jayson Bedford★★★★★★★★★★Raymond James · #819
Hits 60%299 of 498 Average return +8.6%
2 years Matthew Taylor★★★★★★★★★★Jefferies · #1367
Hits 55%250 of 455 Average return +7.2%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $125 at a price of $98.83 (+26.1%); now: $126 at $105 (+19.6%).

$100$110$120Sep 15Oct 1Oct 15Top analysts$124Average target$126Price$105

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0102030152Oct 25221Nov211Dec1211Jan 261171Feb1191Mar203Apr193May263Jun24Jul30Aug24Sep17Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy192624302417
Hold330000
Sell000000

Earnings and sales forecast

Next report: 21.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $1.42 (from $1.40 to $1.44). Last quarter: $1.31.

Sales

Next quarter’s sales estimate — $13.0B (from $12.9B to $13.1B). Last quarter: $12.6B.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Abbott Laboratories
  • CEO: Robert Ford
  • Employees: 115,000
  • 100 Abbott Park Road, Abbott Park, IL, 60064-6400, US
  • www.abbott.com

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm man

Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗